Edit
STA Pharmaceutical, a WuXi AppTec Company (WuXi STA)
http://www.stapharma.com/Last activity: 26.09.2022
Active
WuXi STA, a WuXi AppTec company, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with 14 sites across Asia, North America, and Europe.
As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for small molecule Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Our globally integrated CMC platform supports small molecules, oligonucleotides, peptides and antibody drug conjugates from preclinical to commercial.
Visit WuXi STA website: https://stapharma.com
Visit Peptide CRDMO website: https://peptide.wuxiapptec.com
As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for small molecule Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Our globally integrated CMC platform supports small molecules, oligonucleotides, peptides and antibody drug conjugates from preclinical to commercial.
Visit WuXi STA website: https://stapharma.com
Visit Peptide CRDMO website: https://peptide.wuxiapptec.com
Location: China, Shanghai
Employees: 5001-10000
Founded date: 2000
Investors 1
| Date | Name | Website |
| - | Terra Magn... | terramagnu... |
Mentions in press and media 11
| Date | Title | Description |
| 26.09.2022 | WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility | New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), ... |
| 09.09.2022 | WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers | SHANGHAI, Sept. 9, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. Created in resp... |
| 17.08.2022 | WuXi STA Breaks Ground for New Pharmaceutical Manufacturing Facility in Middletown, Delaware | MIDDLETOWN, Del., Aug. 17, 2022 /PRNewswire/ -- WuXi STA, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the groundbreaking for its new 190-acre pharmaceutical manufacturing campus i... |
| 07.07.2022 | WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility | Site Enhances New Modality CRDMO Platform Capacity for Customers SHANGHAI, July 7, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facili... |
| 07.07.2022 | Manufacturing roundup: WuXi continues its expansion drive with another plant opening in Changzhou; Swiss biotech nets another acquisition | Spurred on by a growing demand for outsourced manufacturing, a slew of CDMO firms have uncorked big expansion plans to keep up. Now, Chinese drugmaker WuXi AppTec is planting its flag in Delaware as part of an ambitious plan to expand its C... |
| 11.02.2022 | WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories | SHANGHAI, Feb. 11, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, Compatibility, Expertise, Quality, Reliability and... |
| 01.07.2021 | Horizon takes the leap into manufacturing, buying out an Irish plant with around 40 employees in tow | Horizon Therapeutics, the biotech known for scooping up orphan drugs, has made its first foray into manufacturing with the purchase of a facility in Waterford, Ireland. EirGen Pharma has sold its site to Horizon for $6... |
| 01.07.2021 | New to the party, Novartis seeks to plunge into mRNA | It’s increasingly unclear just how long Biogen will have the only major Alzheimer’s drug on the market. According to a report from Jefferies, Roche has been in discussions with the FDA on whether they can file their own Alzheimer’s drug for... |
| 01.07.2021 | New to the party, Novartis seeks to plunge into mRNA | After fighting a years-long uphill battle with its oral microbiome candidate SER-109, Seres Therapeutics finally got the Phase III results it was looking for last August. And on Thursday, the company inked a $525 million deal with Nestlé He... |
| 14.05.2021 | WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services | WUXI, China, May 14, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi AppTec, today announced that a joint ven... |
Show more